Trametinib, as a monotherapy, first received its FDA approval for the treatment of some melanomas carrying certain BRAF mutations and was subsequently approved as a combinational therapy for some solid tumors including gliomas and NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.